Dual opposing roles of adaptive immunity in hypertension

European Heart Journal

Volumn 35, Issue 19, 2014, Pages

  Idris Khodja, Noureddine ^a   Mian, Muhammad Oneeb Rehman ^a   Paradis, Pierre ^a   Schiffrin, Ernesto L ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Adaptive immunity; Blood pressure; Cytokines; Inflammation; T effector lymphocytes; T regulatory lymphocytes

Indexed keywords

ADAPTIVE IMMUNITY; CENTRAL NERVOUS SYSTEM; EFFECTOR CELL; HUMAN; HYPERTENSION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH17 CELL; TH2 CELL; ANTIBODY PRODUCTION; HELPER CELL; IMMUNOLOGY; METABOLISM; PHYSIOLOGY;

C REACTIVE PROTEIN; CYTOKINE; IMMUNOGLOBULIN;

ADAPTIVE IMMUNITY; ANTIBODY FORMATION; C-REACTIVE PROTEIN; CENTRAL NERVOUS SYSTEM; CYTOKINES; HUMANS; HYPERTENSION; IMMUNOGLOBULINS; T-LYMPHOCYTES, HELPER-INDUCER; T-LYMPHOCYTES, REGULATORY;

EID: 84901018701     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehu119     Document Type: Review

References (81)

1. Schiffrin EL. Immune mechanisms in hypertension and vascular injury. Clin Sci (Lond) 2014;126:267-274.
2. Harrison DG, Guzik TJ, Lob HE, Madhur MS, Marvar PJ, Thabet SR, Vinh A, Weyand CM. Inflammation, immunity, and hypertension. Hypertension 2011;57: 132-140.
3. MianMO, Paradis P, Schiffrin EL. Innate immunity in hypertension. Curr Hypertens Rep 2014;16:413.
4. Svendsen UG. The importance of thymus in the pathogenesis of the chronic phase of hypertension in mice following partial infarction of the kidney. Acta Pathol Microbiol Scand A 1977;85:539-547.
5. Bataillard A, Freiche JC, Vincent M, Sassard J, Touraine JL. Antihypertensive effect of neonatal thymectomy in the genetically hypertensive LH rat. Thymus 1986;8: 321-330.
6. Olsen F. Transfer of arterial hypertension by splenic cells fromDOCA-salt hypertensive and renal hypertensive rats to normotensive recipients. Acta Pathol Microbiol Scand C 1980;88:1-5.
7. Renaudin C, Bataillard A, Sassard J. Partial transfer of genetic hypertension by lymphoid cells in Lyon rats. J Hypertens 1995;13(12 Pt 2):1589-1592.
8. Hang L, Stephen-Larson PM, Henry JP, Dixon FJ. Transfer of renovascular hypertension and coronary heart disease by lymphoid cells from SLE-prone mice. Am J Pathol 1984;115:42-46.
9. Norman RA Jr., Dzielak DJ, Bost KL, Khraibi AA, Galloway PG. Immune system dysfunctioncontributes to the aetiology of spontaneous hypertension. J Hypertens 1985; 3:261-268.
10. Olsen F, Rasmussen S. Delayed hypersensitivity and borderline essential hypertension. Acta Pathol Microbiol Scand C 1977;85:196-198.
11. Khraibi AA, Norman RA Jr., Dzielak DJ. Chronic immunosuppression attenuates hypertension in Okamoto spontaneously hypertensive rats. Am J Physiol 1984; 247(5 Pt 2):H722-H726.
12. Sitsen JM, de JongW. Development of high blood pressure in spontaneously hypertensive rats is delayed by treatment with cyclosporin at an early age. Experientia 1987; 43:403-405.
13. Carreno BM, Collins M. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu Rev Immunol 2002;20: 29-53.
14. O'Shea JJ, Paul WE. Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells. Science 2010;327:1098-1102.
15. Lord SJ, Rajotte RV, Korbutt GS, Bleackley RC. Granzyme B: a natural born killer. Immunol Rev 2003;193:31-38.
16. Hayday AC. [gamma][delta] cells: a right time and a right place for a conserved third way of protection. Annu Rev Immunol 2000;18:975-1026.
17. Brandes M, Willimann K, Moser B. Professional antigen-presentation function by human gammadelta T Cells. Science 2005;309:264-268.
18. Sutton CE, Lalor SJ, Sweeney CM, Brereton CF, Lavelle EC, Mills KH. Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. Immunity 2009;31:331-341.
19. Otsuka AHS, Miyachi Y, Kabashima K. CD39: A new surface marker of mouse regulatory gd T cells. J Allergy Clin Immunol 2013;132:1448-1451.
20. Lin YZ, WuBW, Lu ZD, Huang Y, Shi Y, Liu H, Liu L, Zeng QT,Wang X, JiQW. Circulating Th22 and Th9 levels in patients with acute coronary syndrome. Mediators Inflamm 2013;2013:635672.
21. Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol 2008;8:523-532.
22. Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur J Immunol 2010;40: 1830-1835.
23. Wang YM, Alexander SI. CD8 regulatory T cells: what's old is now new. Immunol Cell Biol 2009;87:192-193.
24. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, Goronzy J, Weyand C, Harrison DG. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med 2007;204:2449-2460.
25. Wu J, Thabet SR, Kirabo A, Trott DW, Saleh MA, Xiao L, Madhur MS, Chen W, Harrison DG. Inflammation and Mechanical Stretch Promote Aortic Stiffening in Hypertension Through Activation of p38 Mitogen-Activated Protein Kinase. Circ Res 2014;114:616-625.
26. Mattson DL, James L, Berdan EA, Meister CJ. Immune suppression attenuates hypertension and renal disease in the Dahl salt-sensitive rat. Hypertension 2006;48: 149-156.
27. De Miguel C, Das S, Lund H, Mattson DL. T lymphocytes mediate hypertension and kidney damage in Dahl salt-sensitive rats. Am J Physiol Regul Integr Comp Physiol 2010; 298:R1136-R1142.
28. Boesen EI, Williams DL, Pollock JS, PollockDM. Immunosuppression with mycophenolate mofetil attenuates the development of hypertension and albuminuria in deoxycorticosterone acetate-salt hypertensive rats. Clin Exp Pharmacol Physiol 2010; 37:1016-1022.
29. Rodriguez-Iturbe B, Quiroz Y, Nava M, Bonet L, Chavez M, Herrera-Acosta J, Johnson RJ, Pons HA. Reduction of renal immune cell infiltration results in blood pressure control in genetically hypertensive rats. Am J Physiol Renal Physiol 2002; 282:F191-F201.
30. Rodriguez-Iturbe B, Quiroz Y, Ferrebuz A, Parra G, Vaziri ND. Evolution of renal interstitial inflammation and NF-kappaB activation in spontaneously hypertensive rats. Am J Nephrol 2004;24:587-594.
31. Vital SA, Terao S, Nagai M, Granger DN. Mechanisms underlying the cerebral microvascular responses to angiotensin II-induced hypertension. Microcirculation 2010;17: 641-649.
32. Crowley SD, Song YS, Lin EE, Griffiths R, Kim HS, Ruiz P. Lymphocyte responses exacerbate angiotensin II-dependent hypertension.AmJ Physiol Regul Integr CompPhysiol 2010;298:R1089-R1097.
33. Mattson DL, Lund H, Guo C, Rudemiller N, Geurts AM, Jacob H. Genetic mutation of recombination activating gene 1 in Dahl salt-sensitive rats attenuates hypertension and renal damage. Am J Physiol Regul Integr Comp Physiol 2013;304:R407-R414.
34. Crowley SD, Song YS, Sprung G, Griffiths R, Sparks M, Yan M, Burchette JL, HowellDN,Lin EE, Okeiyi B, Stegbauer J, YangY, Tharaux PL, Ruiz P.Arole for angiotensin II type 1 receptors on bone marrow-derived cells in the pathogenesis of angiotensin II-dependent hypertension. Hypertension 2010;55:99-108.
35. Zhang JD, Patel MB, Song YS, Griffiths R, Burchette J, Ruiz P, Sparks MA, Yan M, Howell DN, Gomez JA, Spurney RF, Coffman TM, Crowley SD. A novel role for type 1 angiotensin receptors on T lymphocytes to limit target organ damage in hypertension. Circ Res 2012;110:1604-1617.
36. Gratze P, Dechend R, Stocker C, Park JK, Feldt S, Shagdarsuren E, Wellner M, Gueler F, Rong S, Gross V, Obst M, Plehm R, Alenina N, Zenclussen A, Titze J, Small K, Yokota Y, Zenke M, Luft FC, Muller DN. Novel role for inhibitor of differentiation 2 in the genesis of angiotensin II-induced hypertension. Circulation 2008; 117:2645-2656.
37. Marchesi C, Rehman A, Rautureau Y, Kasal DA, Briet M, Leibowitz A, Simeone SM, Ebrahimian T, Neves MF, Offermanns S, Gonzalez FJ, Paradis P, Schiffrin EL. Protective role of vascular smooth muscle cell PPARgamma in angiotensin II-induced vascular disease. Cardiovasc Res 2013;97:562-570.
38. Diep QN, Amiri F, Touyz RM, Cohn JS, Endemann D, Neves MF, Schiffrin EL. PPARalpha activator effects on Ang II-induced vascular oxidative stress and inflammation. Hypertension 2002;40:866-871.
39. Diep QN, El Mabrouk M, Cohn JS, Endemann D, Amiri F, Virdis A, Neves MF, Schiffrin EL. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensinII-infused rats: role of peroxisome proliferator-activated receptor-gamma. Circulation 2002;105:2296-2302.
40. Senchenkova EY, Russell J, Kurmaeva E, Ostanin D, Granger DN. Role of T lymphocytes in angiotensin II-mediated microvascular thrombosis. Hypertension 2011;58: 959-965.
41. Shao J, Nangaku M, Miyata T, Inagi R, Yamada K, Kurokawa K, Fujita T. Imbalance of T-cell subsets in angiotensin II-infused hypertensive rats with kidney injury. Hypertension 2003;42:31-38.
42. Mazzolai L, Duchosal MA, Korber M, Bouzourene K, Aubert JF, Hao H, Vallet V, Brunner HR, Nussberger J, Gabbiani G, Hayoz D. Endogenous angiotensin II induces atherosclerotic plaque vulnerability and elicits a Th1 response in ApoE-/-mice. Hypertension 2004;44:277-282.
43. Kossmann S, Schwenk M, Hausding M, Karbach SH, Schmidgen MI, Brandt M, Knorr M, Hu H, Kroller-Schon S, Schonfelder T, Grabbe S, Oelze M, Daiber A, Munzel T, Becker C, Wenzel P. Angiotensin II-induced vascular dysfunction depends on interferon-gamma-driven immune cell recruitment and mutual activation of monocytes and NK-cells. Arterioscler Thromb Vasc Biol 2013;33:1313-1319.
44. Tuttle RS, Boppana DP. Antihypertensive effect of interleukin-2. Hypertension 1990; 15:89-94.
45. Ishimitsu T, Uehara Y, Numabe A, Tsukada H, Ogawa Y, Yagi S. Antihypertensive effect of interleukin-2 in salt-sensitive Dahl rats. Hypertension 1994;23:68-73.
46. Given MB, Lowe RF, Williams DL, Sander GE, Giles TD. Failure of interleukin-2 to alter systolic blood pressure in Dahl salt-sensitive rats. Am J Hypertens 1992;5: 203-204.
47. Dzielak DJ. Interleukin-2 and spontaneous hypertension. Hypertension 1991;18: 171-175.
48. van Heuven-Nolsen D, De Kimpe SJ, Muis T, van Ark I, Savelkoul H, Beems RB, van Oosterhout AJ, Nijkamp FP. Opposite role of interferon-gamma and interleukin-4 on the regulation of blood pressure in mice. Biochem Biophys Res Commun 1999; 254:816-820.
49. Ishimitsu T, Uehara Y, Numabe A, Tsukada H, Ogawa Y, Iwai J, Ikeda T, Matsuoka H, Sugimoto T, Yagi S. Interferon gamma attenuates hypertensive renal injury in saltsensitive Dahl rats. Hypertension 1992;19:804-808.
50. XiaY, Entman ML,WangY. Critical role ofCXCL16in hypertensive kidney injury and fibrosis. Hypertension 2013;62:1129-1137.
51. Madhur MS, Lob HE, McCann LA, IwakuraY, BlinderY, Guzik TJ, Harrison DG. Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension 2010;55:500-507.
52. Nguyen H, Chiasson VL, Chatterjee P, Kopriva SE, Young KJ, Mitchell BM. Interleukin-17 causes Rho-kinase-mediated endothelial dysfunction and hypertension. Cardiovasc Res 2013;97:696-704.
53. Amador CA, Barrientos V, Pena J, Herrada AA, Gonzalez M, Valdes S, Carrasco L, Alzamora R, Figueroa F, Kalergis AM, Michea L. Spironolactone decreases DOCA-salt-induced organ damage by blocking the activation of T helper 17 and the downregulation of regulatory T lymphocytes. Hypertension 2014; DOI: 10.1161/HYPERTENSIONAHA.113.02883.
54. Kleinewietfeld M, Manzel A, Titze J, Kvakan H, Yosef N, Linker RA, Muller DN, Hafler DA. Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells. Nature 2013;496:518-522.
55. Wallace K, Richards S, Dhillon P, Weimer A, Edholm ES, Bengten E, Wilson M, Martin JN Jr, LaMarca B. CD4+ T-helper cells stimulated in response to placental ischemia mediate hypertension during pregnancy. Hypertension 2011;57:949-955.
56. Cornelius DC, Hogg JP, Scott J, Wallace K, Herse F, Moseley J, Wallukat G, Dechend R, LaMarca B. Administration of interleukin-17 soluble receptor C suppressesTH17cells, oxidative stress, and hypertension in response to placental ischemia during pregnancy. Hypertension 2013;62:1068-1073.
57. Chiasson VL, Talreja D, Young KJ, Chatterjee P, Banes-Berceli AK, Mitchell BM. FK506 binding protein 12 deficiency in endothelial and hematopoietic cells decreases regulatory T cells and causes hypertension. Hypertension 2011;57: 1167-1175.
58. Herrada AA, Contreras FJ, Marini NP, Amador CA, Gonzalez PA, Cortes CM, Riedel CA, Carvajal CA, Figueroa F, Michea LF, Fardella CE, Kalergis AM. Aldosterone promotes autoimmune damage by enhancing Th17-mediated immunity. J Immunol 2010;184:191-202.
59. Vinh A, Chen W, Blinder Y, Weiss D, Taylor WR, Goronzy JJ, Weyand CM, Harrison DG, Guzik TJ. Inhibition and genetic ablation of the B7/CD28 T-cell costimulation axis prevents experimental hypertension. Circulation 2010;122: 2529-2537.
60. Ganta CK, Lu N, Helwig BG, Blecha F, Ganta RR, Zheng L, Ross CR, Musch TI, Fels RJ, Kenney MJ. Central angiotensin II-enhanced splenic cytokine gene expression is mediated by the sympathetic nervous system. Am J Physiol Heart Circ Physiol 2005; 289:H1683-H1691.
61. Marvar PJ, Thabet SR, Guzik TJ, Lob HE, McCann LA, Weyand C, Gordon FJ, Harrison DG. Central and peripheral mechanisms of T-lymphocyte activation and vascular inflammation produced by angiotensin II-induced hypertension. Circ Res 2010;107:263-270.
62. Lob HE, Marvar PJ, Guzik TJ, Sharma S, McCann LA, Weyand C, Gordon FJ, Harrison DG. Induction of hypertension and peripheral inflammation by reduction of extracellular superoxide dismutase in the central nervous system. Hypertension 2010;55:277-283, 6p following 283.
63. Zimmerman MC, Lazartigues E, Sharma RV, Davisson RL. Hypertension caused by angiotensin II infusion involves increased superoxide production in the central nervous system. Circ Res 2004;95:210-216.
64. Jun JY, Zubcevic J, Qi Y, Afzal A, Carvajal JM, Thinschmidt JS, Grant MB, Mocco J, Raizada MK. Brain-mediated dysregulation of the bone marrow activity in angiotensin II-induced hypertension. Hypertension 2012;60:1316-1323.
65. Viel EC, Lemarie CA, Benkirane K, Paradis P, Schiffrin EL. Immune regulation and vascular inflammation in genetic hypertension. Am J Physiol Heart Circ Physiol 2010;298: H938-H944.
66. Barhoumi T, Kasal DA, LiMW, Shbat L, Laurant P, NevesMF, Paradis P, Schiffrin EL. T regulatory lymphocytes prevent angiotensin II-induced hypertension and vascular injury. Hypertension 2011;57:469-476.
67. Kasal DA, Barhoumi T, Li MW, Yamamoto N, Zdanovich E, Rehman A, Neves MF, Laurant P, Paradis P, Schiffrin EL. T regulatory lymphocytes prevent aldosteroneinduced vascular injury. Hypertension 2012;59:324-330.
68. Kvakan H, Kleinewietfeld M, Qadri F, Park JK, Fischer R, Schwarz I, RahnHP, PlehmR, Wellner M, Elitok S, Gratze P, Dechend R, Luft FC, Muller DN. Regulatory T cells ameliorate angiotensin II-induced cardiac damage. Circulation 2009;119:2904-2912.
69. Matrougui K, Abd Elmageed Z, Kassan M, Choi S, Nair D, Gonzalez-Villalobos RA, Chentoufi AA, Kadowitz P, Belmadani S, Partyka M. Natural regulatory T cells control coronary arteriolar endothelial dysfunction in hypertensive mice. Am J Pathol 2011;178:434-441.
70. Didion SP, KinzenbawDA, Schrader LI, Chu Y, Faraci FM. Endogenous interleukin-10 inhibits angiotensin II-induced vascular dysfunction. Hypertension 2009;54:619-624.
71. Kassan M, Galan M, Partyka M, Trebak M, Matrougui K. Interleukin-10 released by CD4(+)CD25(+) natural regulatory T cells improves microvascular endothelial function through inhibition of NADPH oxidase activity in hypertensive mice. Arterioscler Thromb Vasc Biol 2011;31:2534-2542.
72. Blake GJ, Rifai N, Buring JE, Ridker PM. Blood pressure, C-reactive protein, and risk of future cardiovascular events. Circulation 2003;108:2993-2999.
73. Martinez Amenos A, Buendia E, Carreras L, Font I, Mestre M, Rama H, Sarrias X, Alsina J. Humoral and cellular immunological abnormalities in hypertensive patients. J Clin Hypertens 1985;1:153-160.
74. Smart YC, Gillies AH,WagaSW,Carney SL, Smith AJ, Burton RC. Effects of captopril on circulating T lymphocyte subsets. Int J Clin Pharmacol Ther Toxicol 1987;25: 389-391.
75. Seaberg EC, Munoz A, Lu M, Detels R, Margolick JB, Riddler SA, Williams CM, Phair JP, Multicenter ACS. Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS 2005;19:953-960.
76. Herrera J, Ferrebuz A, MacGregor EG, Rodriguez-Iturbe B. Mycophenolate mofetil treatment improves hypertension in patients with psoriasis and rheumatoid arthritis. J Am Soc Nephrol 2006;17(12 Suppl 3):S218-S225.
77. Ammirati E, Cianflone D, Vecchio V, Banfi M, Vermi AC, De Metrio M, Grigore L, Pellegatta F, Pirillo A, Garlaschelli K, Manfredi AA, Catapano AL, Maseri A, Palini AG, Norata GD. Effector memory T cells are associated with atherosclerosis in humans and animal models. J Am Heart Assoc 2012;1:27-41.
78. Youn JC, Yu HT, Lim BJ, Koh MJ, Lee J, Chang DY, Choi YS, Lee SH, Kang SM, Jang Y, Yoo OJ, Shin EC, Park S. Immunosenescent CD8+ T cells and C-X-C chemokine receptor type 3 chemokines are increased in human hypertension. Hypertension 2013;62:126-133.
79. Santner-Nanan B, Peek MJ, Khanam R, Richarts L, Zhu E, Fazekas de St Groth B, Nanan R. Systemic increase in the ratio between Foxp3+ and IL-17-producing CD4+ T cells in healthy pregnancy but not in preeclampsia. J Immunol 2009;183: 7023-7030.
80. Schiffrin EL. Vascular remodeling in hypertension: mechanisms and treatment. Hypertension 2012;59:367-374.
81. Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and hypertension: a systematic review and meta-analysis of observational studies. J Hypertens 2013;31:433-442; discussion 442-3.